4//SEC Filing
Chang David D 4
Accession 0001737287-25-000017
CIK 0001737287other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 4:13 PM ET
Size
8.0 KB
Accession
0001737287-25-000017
Insider Transaction Report
Form 4
Chang David D
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2025-02-03$1.68/sh−46,003$77,285→ 5,317,237 total
Holdings
- 856,044(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
- 1,201,108(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.68 to $1.69, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above.
- [F3]Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
- [F4]Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
- [F5]Securities held in the name of the Chang 2006 Family Trust
Documents
Issuer
Allogene Therapeutics, Inc.
CIK 0001737287
Entity typeother
Related Parties
1- filerCIK 0001611024
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 4:13 PM ET
- Size
- 8.0 KB